Slide thumbnail
RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.
Slide thumbnail
RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
Slide thumbnail
RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.
NIH NCI SBIR Contract Award for targeted alpha-TAT of metastatic melanoma. The third collaborative grant for Viewpoint and RadioMedix.
Slide thumbnail
Viewpoint MT and RadioMedix secure a second SBIR NCI grant for image guided therapy for metastatic melanoma
AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors
Slide thumbnail
RadioMedix Inc. launches SmartMedix™ synthesizers powered by Trasis in USA
Slide thumbnail
RadioMedix initiates the first Ga-68 PSMA (ProstaMedix™) clinical trial for diagnosis and management of prostate cancer in U.S.
Radiomedix Receives Phase I SBIR Funding from the NCI for Metastatic Melanoma Theranostics
Viewpoint/Radiomedix Partner to Win SBIR Funding
RadioMedix -ViewPointMT collaboration featured on the cover of ACS Carbohydrate Newsletter
Slide thumbnail
RadioMedix Inc. granted exclusive distribution authorization for ITG 68Ge/68Ga generators, and ITG iQS® Ga-68 Fluidic Labelling Module in U.S.A.
[image]
Dr.Tworowska invited to present at the 2013 Biomarkers and Clinical Research Conference
RadioMedix signs collaborative agreement with Viewpoint Molecular Targeting, LLC of Iowa City IA
[image]
RadioMedix presented on the CHI Conference Discovery on Target

Innovating Theranostics

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.

RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

Recent News


RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.

October 31st, 2016|Comments Off on RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.

RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)

October 18th, 2016|Comments Off on RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)

RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.

August 23rd, 2016|Comments Off on RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.

NIH NCI SBIR Contract Award for targeted alpha-TAT of metastatic melanoma. The third collaborative grant for Viewpoint and RadioMedix.

January 21st, 2016|Comments Off on NIH NCI SBIR Contract Award for targeted alpha-TAT of metastatic melanoma. The third collaborative grant for Viewpoint and RadioMedix.

Viewpoint MT and RadioMedix secure a second SBIR NCI grant for image guided therapy for metastatic melanoma

August 17th, 2015|Comments Off on Viewpoint MT and RadioMedix secure a second SBIR NCI grant for image guided therapy for metastatic melanoma

AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors

May 18th, 2015|Comments Off on AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors